Clinical Treatment of Neuroendocrine Neoplasm
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 15 May 2025 | Viewed by 171
Special Issue Editors
Interests: nuclear medicine; peptide receptor radionuclide therapy; endocrinology; oncology; computed tomography
Special Issues, Collections and Topics in MDPI journals
Interests: nuclear medicine; peptide receptor radionuclide therapy; endocrinology; computed tomography; emergency radiology; chest imaging; gastrointestinal imaging; urinary imaging; trauma imaging; bowel imaging; interventional radiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neuroendocrine neoplasms (NENs) constitute a heterogeneous group of malignancies arising from the diffuse neuroendocrine cell system.
Gastro-entero-pancreatic (GEP) NENs account for more than 70% of NENs, followed by the lung. These tumors share the ability to overexpress somatostatin receptors (SSTRs). About 90% of cases are well differentiated forms of neuroendocrine tumors (NETs), with slow proliferation and prolonged surviva rates.
Histological diagnosis is mandatory in all NENs patients, and the neuroendocrine phenotype is proven by the immunohistochemical analysis of the neuroendocrine markers, such as synaptophysin and/or chromogranin A. According to Ki-67 index and mitotic count, the disease stage and tumor grade are two fundamental independent prognostic factors, in-fact the low-grade tumors are classified as grade 1 (G1), intermediate-grades as grade 2 (G2) and high-grades as grade 3 (G3).
Computed tomography (CT) constitutes the primary radiological imaging for NENs to detect the primary and secondary lesions.
In loco-regional disease, surgery is the treatment of choice, while the goal of systemic therapy with somatostatin analogue therapy (SSAs) is to control the clinical symptoms and the tumour growth.
Further systemic therapies are recommended for their antiproliferative effect on NENs patients, such as IFN-a, Everolimus, Chemiotherapy and Sunitinib.
In recent years, nuclear medicine has also played an important role in the management and diagnosis of NENs. In this context positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been approved by the European Medicines Agency and Food and Drug Administration in the pathway of these patients.
Dr. Michele Klain
Guest Editor
Dr. Leandra Piscopo
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine neoplasms
- neuroendocrine cell system
- gastro-entero-pancreatic NENs
- immunohistochemical analysis
- Ki-67 index
- mitotic count
- somatostatin analogue therapy
- antiproliferative effect
- positron emission tomography/computed tomography (PET/CT)
- peptide receptor radionuclide therapy (PRRT)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
